Canandaigua National Bank & Trust Co. Purchases Shares of 83,853 Merck & Co., Inc. $MRK

Canandaigua National Bank & Trust Co. bought a new stake in shares of Merck & Co., Inc. (NYSE:MRK) during the 2nd quarter, Holdings Channel reports. The fund bought 83,853 shares of the company’s stock, valued at approximately $10,775,000. Merck & Co., Inc. makes up 0.9% of Canandaigua National Bank & Trust Co.’s portfolio, making the stock its 23rd biggest holding.

A number of other hedge funds and other institutional investors also recently made changes to their positions in MRK. Kingdom Financial Group LLC. purchased a new position in Merck & Co., Inc. during the 4th quarter valued at $25,000. Prosperity Bancshares Inc purchased a new stake in shares of Merck & Co., Inc. in the 4th quarter worth about $26,000. Abound Financial LLC bought a new stake in shares of Merck & Co., Inc. during the 4th quarter valued at about $26,000. IFC & Insurance Marketing Inc. bought a new stake in shares of Merck & Co., Inc. during the 4th quarter valued at about $31,000. Finally, High Note Wealth LLC increased its position in shares of Merck & Co., Inc. by 58.9% during the fourth quarter. High Note Wealth LLC now owns 294 shares of the company’s stock valued at $31,000 after buying an additional 109 shares during the period. Institutional investors own 76.07% of the company’s stock.

Merck & Co., Inc. Trading Up 0.4%

Shares of NYSE MRK opened at $128.28 on Wednesday. Merck & Co., Inc. has a 1 year low of $77.58 and a 1 year high of $135.05. The stock has a market cap of $316.83 billion, a P/E ratio of 36.14, a price-to-earnings-growth ratio of 5.07 and a beta of 0.19. The firm has a 50-day moving average of $123.45 and a 200 day moving average of $118.78. The company has a debt-to-equity ratio of 1.02, a current ratio of 1.30 and a quick ratio of 1.06.

Merck & Co., Inc. (NYSE:MRK) last announced its quarterly earnings data on Tuesday, August 4th. The company reported ($0.13) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.13. Merck & Co., Inc. had a net margin of 13.59% and a return on equity of 27.55%. The business had revenue of $16.61 billion for the quarter, compared to analysts’ expectations of $16.37 billion. During the same quarter in the prior year, the company earned $2.13 earnings per share. The business’s revenue was up 5.1% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. As a group, sell-side analysts expect that Merck & Co., Inc. will post 2.74 EPS for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, October 7th. Investors of record on Tuesday, September 15th will be paid a $0.85 dividend. The ex-dividend date is Tuesday, September 15th. This represents a $3.40 annualized dividend and a dividend yield of 2.7%. Merck & Co., Inc.’s dividend payout ratio is presently 95.77%.

Merck & Co., Inc. News Summary

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck reported second-quarter revenue of $16.61 billion, above the $16.37 billion consensus estimate and up 5.1% year over year. Adjusted loss per share of $0.13 was also better than the expected $0.26 loss. Merck posts better-than-expected second-quarter results on Keytruda strength
• Positive Sentiment: Keytruda remained the primary growth engine, while the newer injectable version of the cancer treatment exceeded Wall Street expectations by more than $200 million. Strength in oncology and other newer products helped support the improved sales outlook. The Merck Product That Absolutely Demolished Wall Street’s Forecasts
• Positive Sentiment: Merck raised and narrowed its full-year 2026 revenue forecast to $66.3 billion-$67.3 billion, broadly consistent with the $66.7 billion analyst consensus. Management also highlighted regulatory, clinical and pipeline milestones that could support longer-term growth. MRK Q2 Earnings and Sales Beat Estimates, 2026 Sales View Raised
• Negative Sentiment: Merck cut its 2026 EPS guidance to $2.66-$2.76, well below the $3.42 consensus estimate, because of charges associated with the acquisition of Terns Pharmaceuticals. The resulting earnings pressure offsets part of the benefit from the stronger sales outlook. Merck hikes revenue outlook but cuts profit guidance due to deal charges

Wall Street Analysts Forecast Growth

Several analysts have commented on MRK shares. Weiss Ratings lowered shares of Merck & Co., Inc. from a “hold (c+)” rating to a “hold (c)” rating in a report on Friday, May 15th. Morgan Stanley upped their target price on Merck & Co., Inc. from $112.00 to $113.00 and gave the stock an “equal weight” rating in a report on Thursday, July 9th. Wells Fargo & Company increased their target price on Merck & Co., Inc. from $145.00 to $150.00 and gave the stock an “overweight” rating in a research report on Wednesday, July 8th. Cantor Fitzgerald restated a “neutral” rating and issued a $120.00 target price on shares of Merck & Co., Inc. in a research note on Monday, July 6th. Finally, JPMorgan Chase & Co. lifted their price target on Merck & Co., Inc. from $135.00 to $140.00 and gave the company an “overweight” rating in a research report on Monday, July 13th. Thirteen analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $134.50.

Merck & Co., Inc. Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.